Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What key factors are powering the surge in the hepatitis d market right now?

In recent times, the hepatitis D market has experienced consistent growth. The market size, which is predicted to rise from $0.72 billion in 2024 to $0.76 billion in 2025, marks a compound annual growth rate (CAGR) of 4.6%. Factors such as limited therapy alternatives, high occurrence rates in endemic areas, concurrent infection with hepatitis B, inadequate awareness and identification rates, along with government vaccination initiatives, have contributed to this growth witnessed in the historic period.

How fast Is the hepatitis d market expected to grow, and what’s its future value?

Forecasts suggest a continuous, stable increase in the hepatitis D market size over the coming years, culminating in a total valuation of $0.90 billion by 2029, reflecting a compound annual growth rate (CAGR) of 4.4%. This growth during the projected timeline can be associated with the broadening of reimbursement policies for innovative treatments, heightened investment in the healthcare division, escalating adoption of combined treatment strategies, an increase in hepatitis B vaccination rates, and the expansion of public health campaigns. Key trends for the forecast period encompass the evolution of molecular diagnostic instruments, a tilt towards personalised medicine for managing liver ailments, advancements in novel RNA-based therapies, an increase in clinical trials focussed on hepatitis D treatments, and the adoption of telemedicine for managing hepatitis.

Get your hepatitis d market report here!

https://www.thebusinessresearchcompany.com/report/hepatitis-d-global-market-report

What are the leading drivers of growth in the hepatitis d market?

The rise in the number of hepatitis B cases is predicted to spur the expansion of the hepatitis D market. Hepatitis B is a viral infection targeting the liver, resulting in symptoms such as jaundice, exhaustion, and stomach pain and can transform into chronic liver disease or liver cancer if not treated timely. Factors like unprotected sexual activity, common usage of needles, transmission from mother to child during birth, and inadequate vaccination in specific areas contribute to the increase in Hepatitis B infections. The Hepatitis D virus relies on the Hepatitis B virus to reproduce, utilizing the surface antigen of Hepatitis B to infiltrate liver cells. This makes the co-infection of both viruses a crucial element in the progression of liver disease. For example, a US-based government department, the Department of Health and Human Services, reported in November 2023 that new cases of chronic hepatitis B increased by 11% in 2022 compared to 2021. As a result, the escalating occurrence of hepatitis B is fueling the growth of the hepatitis D market.

What are the key segments defining the hepatitis d market?

The hepatitis d market covered in this report is segmented –

1) By Type: Acute, Chronic

2) By Diagnosis: Blood Tests, Elastography, Liver Biopsy, Serologic Testing, Other Diagnosis

3) By Distribution Channel: Hospital pharmacies, Retail pharmacies, Online Pharmacies

4) By End-Users: Clinic, Hospital, Other End Users

Subsegments:

1) By Acute: Self-limiting Acute Hepatitis D, Severe Acute Hepatitis D

2) By Chronic: Compensated Chronic Hepatitis D, Decompensated Chronic Hepatitis D

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21202&type=smp

Who are the key players steering the development of the hepatitis d market?

Major companies operating in the hepatitis d market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bristol-Myers Squibb Company, Abbott Laboratories, GSK plc, Gilead Sciences Inc., Viatris Inc, VBI Vaccines Inc, Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dynavax Technologies Corporation, Echosens S.A, Arbutus Biopharma Corporation, PROBIOMED SA de CV, Assembly Biosciences Inc., Replicor Inc., Eiger BioPharmaceuticals Inc, Bluejay Therapeutics Inc, Janssen Pharmaceuticals Inc., Transgene SA, Vir Biotechnology Inc, Biorex Diagnostics Ltd.

How are evolving market trends shaping hepatitis d Strategies?

Key players in the hepatitis D market are focusing on developing revolutionary formulations such as recombinant vaccines to boost immunization effectiveness and offer durable protection against the virus. Recombinant vaccines are created by inserting a gene encoding a viral protein into a host organism like bacteria or yeast to produce the protein, which then induces an immune response without causing the disease. For example, in December 2022, VBI Vaccines Inc., a biotech firm headquartered in the US, earned Health Canada approval for PreHevbrio [3-antigen Hepatitis B Vaccine (Recombinant)], an active immunization vaccine against all identified subtypes of hepatitis B in adults 18 years and older. The approval also covers prevention of hepatitis D because it is triggered by the delta agent, which cannot exist without a hepatitis B infection. The endorsement is built on favorable outcomes from two key Phase 3 clinical trials, protect and constant, illustrating higher seroprotection rates with PreHevbrio compared to the single-antigen Engerix-B vaccine.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21202

Which regions are most influential in expanding the hepatitis d market?

North America was the largest region in the hepatitis D market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis d market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Hemophilia Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hemophilia-global-market-report

Acquired Hemophilia Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/acquired-hemophilia-treatment-global-market-report

Insulin Pens, Syringes, Pumps And Injectors Global Market Report 2025

https://thebusinessresearchcompany.com/report/insulin-pens-syringes-pumps-and-injectors-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: